Herbas VPB

Print
EN | LT
LT - Vėžio gydymas naudojant anti-CD19 chimerinį antigeno receptorių
EN - TREATMENT OF CANCER USING ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR

Legal status

Patent in force

Bibliographic data
Indications of the International Patent Classification (IPC)
(51) INT.CL. A61K 39/00 (2006.01)
A61K 35/17 (2015.01)
A61K 31/436 (2006.01)
A61P 35/02 (2006.01)
European patent
(11) Number of the document 3888674
(13) Kind of document T
(96) European patent application number 21160203.2
Date of filing the European patent application 2015-04-07
(97) Date of publication of the European application 2021-10-06
(45) Date of publication and mention of the grant of the patent 2024-04-03
(46) Date of publication of the claims translation 2024-07-25
Priority applications
(30) Number Date Country code
201461976396 P 2014-04-07 US
201462007309 P 2014-06-03 US
201462036493 P 2014-08-12 US
201462076238 P 2014-11-06 US
201462087888 P 2014-12-05 US
201462097278 P 2014-12-29 US
Inventors
(72)
BYRD, John , US
DUBOVSKY, Jason , US
FRAIETTA, Joseph , US
GILL, Saar , US
GLASS, David , US
JOHNSON, Amy , US
JUNE, Carl H. , US
KENDERIAN, Saad , US
MANNICK, Joan , US
MAUS, Marcela , US
MURPHY, Leon , US
MUTHUSAMY, Natarajan , US
PORTER, David L. , US
RUELLA, Marco , US
SELLERS, William Raj , US
WASIK, Mariusz , US
BROGDON, Jennifer , US
Grantee
(73) Novartis AG , Lichtstrasse 35, 4056 Basel, CH
The Trustees of The University of Pennsylvania , 3600 Civic Center Boulevard, 9th Floor, Philadelphia, PA 19104, US
Attorney or representative
(74) Vitalija BANAITIENĖ, UAB TARPINĖ, A.P.Kavoliuko g. 24-152, LT-04328 Vilnius, LT
Title
(54) Vėžio gydymas naudojant anti-CD19 chimerinį antigeno receptorių
  TREATMENT OF CANCER USING ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR
Last renewal fee
Payment date Validity (years) Amount
2025-03-18 11 289.00 EUR
Next renewal fee
2026-04-07